Cargando…
Assessment of compatibility of rhIGF-1/rhIGFBP-3 with neonatal intravenous medications
BACKGROUND: Recombinant human (rh)IGF-1/IGFBP-3 protein complex, administered as a continuous intravenous infusion in preterm infants, is being studied for the prevention of complications of prematurity. METHODS: We conducted in vitro studies to evaluate the physical and chemical compatibility of rh...
Autores principales: | Salamat-Miller, Nazila, Turner, Mark A., Bandekar, Amey, Dixit, Nitin, Jochim, Emily, Mangum, Barry, McPherson, Christopher, Tenjarla, Srini, Singh, Sukhjeet, Hwang, You Seok, Barton, Norman |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832074/ https://www.ncbi.nlm.nih.gov/pubmed/36344872 http://dx.doi.org/10.1007/s12519-022-00610-9 |
Ejemplares similares
-
rhIGF-1/rhIGFBP-3 in Preterm Infants: A Phase 2 Randomized Controlled Trial
por: Ley, David, et al.
Publicado: (2018) -
Pilot dose-ranging of rhIGF-1/rhIGFBP-3 in a preterm lamb model of evolving bronchopulmonary dysplasia
por: Albertine, Kurt H., et al.
Publicado: (2023) -
Randomized Control Trial of Postnatal rhIGF-1/rhIGFBP-3 Replacement in Preterm Infants: Post-hoc Analysis of Its Effect on Brain Injury
por: Horsch, Sandra, et al.
Publicado: (2020) -
rhIGF-1 Therapy: A Silver Bullet for Bronchopulmonary Dysplasia
Prevention?
por: Plosa, Erin J., et al.
Publicado: (2020) -
Effectiveness and safety of rhIGF1 therapy in patients with or without Laron syndrome
por: Bang, Peter, et al.
Publicado: (2020)